Press Releases

RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will

Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents sufficient to fund operations and capital expenditures into 2029 Appointed former GSK CEO Jean-Pierre

Two presentations to highlight increased weight loss in obese mice treated with azelaprag in combination with multiple oral appetite suppressants, and significant protection against weight gain with azelaprag monotherapy RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.

RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that Kristen Fortney, PhD, CEO and

RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the closing of its

RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of aging, today announced the pricing of its

RICHMOND, Calif.--( BUSINESS WIRE )--BioAge Labs, Inc. (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the appointment of Jean-Pierre Garnier, PhD, as Chair of the

Trial to evaluate weight loss efficacy of azelaprag, an oral small molecule apelin receptor agonist that mimics key biological effects of exercise STRIDES is being conducted in collaboration with Lilly’s Chorus clinical development organization Primary endpoint is weight loss at 24 weeks, with

Oral presentation delivered by Chief Medical Officer Paul Rubin, MD, at the American Diabetes Association's 84th Scientific Sessions, the world’s largest diabetes conference RICHMOND, Calif.--( BUSINESS WIRE )--BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing

Newly appointed advisors are world-renowned experts in obesity, diabetes, and cardiometabolic diseases, spanning basic biology to late-stage development RICHMOND, Calif.--( BUSINESS WIRE )--BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic candidates for